Answers are grounded in this paper and cite their sources.
This paper reports design challenges of implementing response-adaptive randomisation in rare-disease trials, suggesting solutions for allocation probabilities and missing data.
Although response-adaptive randomisation (RAR) has gained substantial attention in the literature, it still has limited use in clinical trials. Amongst other reasons, the implementation of RAR in real world trials raises important practical questions, often neglected in the technical literature. Motivated by an innovative phase-II stratified RAR rare-disease trial, this paper addresses two challenges: (1) How to ensure that RAR allocations are desirable, that is, both acceptable and faithful to the intended probabilities, particularly in small samples? and (2) What adaptations to trigger after interim analyses in the presence of missing data? To answer (1), we propose a Mapping strategy that discretises the randomisation probabilities into a vector of allocation ratios, resulting in improved frequentist errors. Under the implementation of Mapping , we answer (2) by analysing the impact of missing data on operating characteristics in selected scenarios. Finally, we discuss additional concerns including: pooling data across trial strata, analysing the level of blinding in the trial, and reporting safety results.
No takes yet. Share an insight, caveat, or question.
Das et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: